AMAG Pharmaceuticals Appoints Laura Williams, M.D. as Senior Vice President of Clinical Development
September 07 2017 - 8:00AM
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the
appointment of Laura Williams, M.D., M.P.H., as senior vice
president of clinical development effective immediately. She
will report to Julie Krop, M.D., chief medical officer and senior
vice president of clinical development and regulatory affairs at
AMAG.
Dr. Williams has more than 20 years of pharmaceutical
experience, spanning all phases of drug development and across
numerous therapeutic areas, including her more recent work with
compounds and products aimed at solving unmet medical needs in
women’s health. In her role at AMAG, Dr. Williams is
responsible for the overall strategy and execution of clinical
development activities, including study design and data
interpretation. She will work with the regulatory, quality,
clinical and technical operations teams to support new drug
development, as well as regulatory filings and approvals.
“Laura brings to AMAG a unique and proven track record of
leading the clinical development strategy for products in the
women’s health therapeutic area,” said Dr. Krop. “With her
experience of evaluating and developing products, Laura will be an
integral member of the team as we look to broaden our portfolio of
women’s health products.”
Prior to joining AMAG, she served as vice president of clinical
development at Myovant Sciences, where she oversaw clinical
development for an infertility treatment and co-led business
development activities to expand the women’s health pipeline.
Previously, she held roles of increasing responsibility at Abbott
and AbbVie where her most recent key achievements included leading
the development program for an oral GnRH antagonist in women’s
health and advancing that mid-late stage asset through multiple key
drug development milestones. At Abbott, she also served as
global project head of numerous clinical development teams across a
range of therapeutic areas.
Dr. Williams received a medical degree from University of Iowa
College of Medicine, a Master of Public Health in Epidemiology from
University of Washington School of Public Health and a Bachelor of
Science from Mississippi State University. She completed her
residency at University of Michigan Hospitals and Clinics and a
fellowship in Infectious Diseases at University of Washington
Hospitals and Clinics.
Inducement Equity Awards In connection with Dr.
Williams entering into employment with AMAG, the Board of Directors
of AMAG approved awards to Dr. Williams of (i) an option to
purchase 28,000 shares of common stock and (ii) 6,000 restricted
stock units. The option will have an exercise price equal to the
closing price of AMAG's common stock on the grant date and will be
exercisable in four equal annual installments beginning on the
first anniversary of the grant date. The option will have a
ten-year term and be subject to the terms and conditions of the
stock option agreement pursuant to which the option will be
granted. The restricted stock units will vest in three equal annual
installments beginning on the first anniversary of the grant date
and will be subject to the restricted stock unit agreement pursuant
to which the restricted stock units will be granted. These equity
awards will be granted without stockholder approval as inducements
material to Dr. Williams entering into employment with AMAG in
accordance with NASDAQ Listing Rule 5635(c)(4).
About AMAGAMAG is a biopharmaceutical company
focused on developing and delivering important therapeutics,
conducting clinical research in areas of unmet need and creating
education and support programs for the patients and families we
serve. Our currently marketed products support the health of
patients in the areas of maternal and women’s health, anemia
management and cancer supportive care. Through CBR®, we also help
families to preserve newborn stem cells, which are used today in
transplant medicine for certain cancers and blood, immune and
metabolic disorders, and have the potential to play a valuable role
in the ongoing development of regenerative medicine. For additional
company information, please
visit www.amagpharma.com.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and other federal
securities laws. Any statements contained herein which do not
describe historical facts, including but not limited to statements
regarding Dr. Williams’ responsibilities at AMAG related to the
overall strategy and execution of clinical development activities,
including study design and data interpretation; AMAG’s belief that
Dr. Williams will be an integral member of the AMAG team as it
broadens its portfolio of women’s health products; and beliefs that
newborn stem cells have the potential to play a valuable role in
the development of regenerative medicine are forward-looking
statements which involve risks and uncertainties that could cause
actual results to differ materially from those discussed in such
forward-looking statements.
Such risks and uncertainties include, among others, those
identified in AMAG’s Securities and Exchange Commission (SEC)
filings, including AMAG’s Annual Report on Form 10-K for the year
ended December 31, 2016 and subsequent filings with the SEC. We
caution you not to place undue reliance on any forward-looking
statements, which speak only as of the date they are made.
AMAG disclaims any obligation to publicly update or revise any
such statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward-looking statements.
AMAG Pharmaceuticals® is a registered trademark of AMAG
Pharmaceuticals, Inc. CBR® is a registered trademark
of CBR Systems, Inc.
AMAG Pharmaceuticals, Inc. Contacts:
Media:
Rushmie Nofsinger
Executive Director, Corporate Communications & Alliance Engagement
617-498-3332
Investors:
Christi Waarich
Associate Director, Investor Relations
617-498-7638
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Aug 2024 to Sep 2024
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Sep 2023 to Sep 2024